ATYR Stock Summary and Trading Ideas (Atyr Pharma | NASDAQ:ATYR)

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Atyr Pharma trades on the NASDAQ stock market under the symbol ATYR.

As of December 19, 2025, ATYR stock price climbed to $0.75 with 5,567,808 million shares trading.

ATYR has a beta of 0.73, meaning it tends to be less sensitive to market movements. ATYR has a correlation of 0.00 to the broad based SPY ETF.

ATYR has a market cap of $73.49 million. This is considered a Micro Cap stock.

Last quarter Atyr Pharma reported $0 in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.07.

The top ETF exchange traded funds that ATYR belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

ATYR has underperformed the market in the last year with a price return of -76.2% while the SPY ETF gained +18.1%. ATYR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.4% and -9.0%, respectively, while the SPY returned +2.8% and -0.5%, respectively.

ATYR support price is $.67 and resistance is $.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATYR shares will trade within this expected range on the day.